The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients

Background: Long-Interspersed Nuclear Element (L1) retrotransposons are silenced in healthy tissues but unrepressed in cancer. Even if L1 reactivation has been associated with reduced overall survival in breast cancer (BC) patients, a comprehensive correlation with clinicopathological features is still missing. Methods: Using quantitative, reverse-transcription PCR, we assessed L1 mRNA expression in 12 BC cells, 210 BC patients and in 47 normal mammary tissues. L1 expression was then correlated with molecular and clinicopathological data. Results: We identified a tumor-exclusive expression of L1s, absent in normal mammary cells and tissues. A positive correlation between L1 expression and tumor dedifferentiation, lymph-node involvement and increased immune infiltration was detected. Molecular subtyping highlighted an enrichment of L1s in basal-like cells and cancers. By exploring disease-free survival, we identified L1 overexpression as an independent biomarker for patients with a high risk of recurrence in hormone-receptor-negative BCs. Conclusions: Overall, L1 reactivation identified BCs with aggressive features and patients with a worse clinical fate.

[1]  L. Ding,et al.  LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint , 2022, Proceedings of the National Academy of Sciences.

[2]  V. Ranzani,et al.  LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion , 2022, Nature Genetics.

[3]  Yujie Sun,et al.  Paclitaxel-induced stress granules increase LINE-1 mRNA stability to promote drug resistance in breast cancer cells , 2021, Journal of biomedical research.

[4]  A. Sapino,et al.  Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction , 2021, Clinical epigenetics.

[5]  Anh Nguyen-Duc,et al.  Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study , 2021, Journal of the National Cancer Institute.

[6]  Ahn, Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[7]  P. Provero,et al.  MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer , 2020, ESMO Open.

[8]  I. Mamedov,et al.  Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers , 2020, Cells.

[9]  Rui Zhang,et al.  New Understanding of the Relevant Role of LINE-1 Retrotransposition in Human Disease and Immune Modulation , 2020, Frontiers in Cell and Developmental Biology.

[10]  J. Dahlstrom,et al.  Efavirenz as a potential drug for the treatment of triple-negative breast cancers , 2020, Clinical and Translational Oncology.

[11]  J. Deleuze,et al.  Tumor DNA hypomethylation of LINE-1 is associated with low tumor grade of breast cancer in Tunisian patients. , 2020, Oncology letters.

[12]  G. Faulkner,et al.  Nanopore sequencing enables comprehensive transposable element epigenomic profiling , 2020, bioRxiv.

[13]  A. Sapino,et al.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas , 2020, Pathobiology.

[14]  P. Mandal,et al.  LINE-1 retrotransposon encoded ORF1p expression and promoter methylation in oral squamous cell carcinoma: a pilot study. , 2020, Cancer genetics.

[15]  David T. W. Jones,et al.  Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition , 2020, Nature Genetics.

[16]  S. Devine,et al.  Aberrantly High Levels of Somatic LINE-1 Expression and Retrotransposition in Human Neurological Disorders , 2020, Frontiers in Genetics.

[17]  H. Krause,et al.  Long Noncoding RNAs and Repetitive Elements: Junk or Intimate Evolutionary Partners? , 2019, Trends in genetics : TIG.

[18]  Sung-Bae Kim,et al.  Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  L. Thuler,et al.  Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. , 2019, European journal of breast health.

[20]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[21]  I. Shih,et al.  Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. , 2019, The American journal of pathology.

[22]  X. Guan,et al.  Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[23]  A. Sapino,et al.  The expression of LINE1‐MET chimeric transcript identifies a subgroup of aggressive breast cancers , 2018, International journal of cancer.

[24]  A. Vincent-Salomon,et al.  The Dilemma of HER2 Double-equivocal Breast Carcinomas , 2018, The American journal of surgical pathology.

[25]  J. Boeke,et al.  Cycling to Maintain and Improve Fitness: Line-1 Modes of Nuclear Entrance and Retrotransposition , 2018, SLAS discovery : advancing life sciences R & D.

[26]  N. Rodić LINE-1 activity and regulation in cancer. , 2018, Frontiers in bioscience.

[27]  Sean Ferree,et al.  PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. V. Moran,et al.  Mobile DNA in Health and Disease , 2017, The New England journal of medicine.

[29]  K. Burns Transposable elements in cancer , 2017, Nature Reviews Cancer.

[30]  Frederick S. Vizeacoumar,et al.  Molecular characterization of breast cancer cell lines through multiple omic approaches , 2017, Breast Cancer Research.

[31]  K. Burns,et al.  The Human Long Interspersed Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia. , 2017, Clinical chemistry.

[32]  R. Meehan,et al.  Decoupling of DNA methylation and activity of intergenic LINE-1 promoters in colorectal cancer , 2017, Epigenetics.

[33]  A. Sapino,et al.  Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis , 2017, British Journal of Cancer.

[34]  Fang Yang,et al.  Multiple LINEs of retrotransposon silencing mechanisms in the mammalian germline. , 2016, Seminars in cell & developmental biology.

[35]  Jacqueline R. Kemp,et al.  Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer , 2015, Front. Chem..

[36]  E. Mardis,et al.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.

[37]  J Cuzick,et al.  Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  J. V. Moran,et al.  The Influence of LINE-1 and SINE Retrotransposons on Mammalian Genomes , 2015, Microbiology spectrum.

[39]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Sean Ferree,et al.  Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens , 2014, BMC Cancer.

[41]  J. Dahlstrom,et al.  Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells , 2013, Breast Cancer Research and Treatment.

[42]  J. Dahlstrom,et al.  Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer , 2012, Breast Cancer Research and Treatment.

[43]  Jane E Dahlstrom,et al.  Naturally occurring endo-siRNA silences LINE-1 retrotransposons in human cells through DNA methylation , 2012, Epigenetics.

[44]  H. Putter,et al.  Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study , 2012, Breast Cancer Research and Treatment.

[45]  N. Henry,et al.  Cancer biomarkers , 2012, Molecular oncology.

[46]  J. V. Moran,et al.  LINE-1 elements in structural variation and disease. , 2011, Annual review of genomics and human genetics.

[47]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  O. J. Semmes,et al.  Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells , 2006, Cancer Cell International.

[49]  Thomas Dandekar,et al.  L1Base: from functional annotation to prediction of active LINE-1 elements , 2004, Nucleic Acids Res..

[50]  Apiwat Mutirangura,et al.  Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis , 2004, Oncogene.

[51]  M. Noguchi,et al.  Prognosis of Node-Positive Breast Cancer Patients Who Underwent Parasternal Lymph Node Biopsy During Surgery Followed by Doxorubicin- or Mitoxantrone-Containing Adjuvant Chemotherapy , 2000, Journal of chemotherapy.

[52]  K. Kinzler,et al.  Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. , 1992, Cancer research.

[53]  C. Carter,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.

[54]  J. Spandorfer,et al.  Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma , 1988, Nature.

[55]  M. Bergmann,et al.  A role of LINE-1 in telomere regulation. , 2018, Frontiers in bioscience.

[56]  Kyoung-Mee Kim,et al.  Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine. , 2017, The Journal of molecular diagnostics : JMD.

[57]  E. Gelmann,et al.  Differentiation state and invasiveness of human breast cancer cell lines , 2004, Breast Cancer Research and Treatment.